Safety and efficacy of transarterial chemoembolization (TACE) combined with apatinib (TACE-apatinib) in patients with Barcelona Clinic Liver Cancer (BCLC) stage C of hepatocellular carcinoma: A retrospective controlled study

Trial Profile

Safety and efficacy of transarterial chemoembolization (TACE) combined with apatinib (TACE-apatinib) in patients with Barcelona Clinic Liver Cancer (BCLC) stage C of hepatocellular carcinoma: A retrospective controlled study

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Feb 2018 New trial record
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top